Affymetrix Launches New OncoScan™ FFPE Assay Kit

  Affymetrix Launches New OncoScan™ FFPE Assay Kit

 Breakthrough assay provides genome wide solid tumor copy number analysis in
                    only 48 hours from only 80ng input DNA

Business Wire

SANTA CLARA, Calif. -- August 5, 2013

Affymetrix, Inc. (NASDAQ: AFFX) announced the launch of the new OncoScan™ FFPE
Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid
tumor samples, at the Cancer Cytogenomics Microarray Consortium conference
being held in Chicago this week.

Despite the growing need of cancer researchers and clinicians, obtaining
high-quality, whole-genome copy number data from degraded FFPE-derived tumor
DNA has remained extremely challenging due to the limitations of current
methods such as FISH, array CGH, and next-generation sequencing technologies.

The new OncoScan FFPE Assay Kit, utilizing Affymetrix’ unique Molecular
Inversion Probe (MIP) technology, is capable of analyzing small amounts of
highly degraded DNA from FFPE samples quickly and affordably, providing a
significant step forward in solid tumor cancer analysis.

This new product provides whole-genome copy number data with specifically
enhanced high resolution in approximately 900 known cancer genes, loss of
heterozygozity (LOH) across the whole genome as well as clinically relevant
somatic mutation data − all from a single assay. An updated version of
BioDiscovery’s Nexus software, OncoScan™ Nexus Express Software, enables copy
number calls for hundreds of samples in minutes and will be included with the
product.

The new kit was successfully tested earlier this year in leading cancer
research institutes, including M. D. Anderson Cancer Center, Memorial Sloan
Kettering Cancer Center, and ARUP Laboratories.

“We performed testing of the new OncoScan™ FFPE Assay Kit at ARUP on multiple
solid tumor tissues, including melanoma, glioma, breast carcinoma, and
liposarcoma,” commented Sarah South, Medical Director at ARUP Laboratories.
“We used the recommended 80 ng of DNA from FFPE and were able to complete the
assay over a 48-hour period. We were able to detect FISH-confirmed aberrations
in several key cancer genes including ERBB2, MDM2, EGFR, and MYC suggesting
that OncoScan FFPE Assay Kit can be considered a viable higher resolution and
higher specificity alternative to FISH testing for confirmation of cancer gene
aberrations in solid tumor tissue. Because OncoScan FFPE Assay Kit has
whole-genome resolution, we also obtained valuable incremental copy number
aberrations in these samples.”

Professor Torsten Pietsch, MD, PhD, Institute of Neuropathology, University of
Bonn observed that based on his experience with a large cohort of FFPE brain
tumor samples, “We believe that the OncoScan FFPE Assay Kit is a robust
platform for the rapid discovery and validation of novel prognostic copy
number signatures, that may also be useful in a clinical setting for the
detection of specific gains in tumors as markers for patient stratification.”

“The significance of copy number aberrations is being established in an ever
increasing number of genes; however, few studies have realized this potential
for solid tumors because of the challenges of working with low-input FFPE
samples,” said Andy Last, Executive Vice President of the Genetic Analysis and
Clinical Applications Business Unit at Affymetrix. “OncoScan FFPE Assay Kit is
a game changer for cancer laboratories that want to quickly and affordably
analyze hundreds of degraded FFPE samples to correlate copy number aberrations
with outcomes data. In addition, the ability to detect a range of clinically
relevant somatic mutations adds even more value to the assay and analysis.”

The technology has previously been made available via the OncoScan™ FFPE
Express 2.0 Service from the Affymetrix Research Services Laboratory and has
demonstrated an unparalleled success rate, with more than 70 publications in
the last two years. The platform enables detection in highly degraded samples
unlocking a wealth of stored information in FFPE archives of ten years and
older.

Affymetrix is accepting orders immediately and will begin shipping the product
as early as September this year.

PLEASE NOTE: Affymetrix^®, the Affymetrix logo, and OncoScan™ trademarks are
the property of Affymetrix, Inc. All other trademarks are the property of
their respective owners.

Products mentioned in this release are for research use only. Not for
diagnostic procedures.

SOURCE: Affymetrix, Inc.

Forward-looking statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2012, and other SEC reports for subsequent quarterly periods.

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of
biological systems at the cell, protein, and gene level, facilitating the
rapid translation of bench-top research into clinical and routine use for
human health and wellness.

We strive to provide leadership and support, partnering with our customers in
pharmaceutical, diagnostic, and biotechnology companies, as well as leading
academic, government, and non-profit research institutes in their quest for
answers toward using biology for a better world.

More than 2,300 microarray systems have been shipped around the world and more
than 48,000 peer-reviewed papers have been published citing our technologies.
Affymetrix is headquartered in Santa Clara, California, and has manufacturing
facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company
has about 1,100 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.

Contact:

Affymetrix, Inc.
Media Contact:
Mindy Lee-Olsen, 408-731-5523
Vice President, Marketing Services
mindy_lee-olsen@affymetrix.com
or
Investor Contact:
Doug Farrell, 408-731-5285
Vice President, Investor Relations
doug_farrell@affymetrix.com